Form 4: United Therapeutics Exec Sells Shares Under 10b5-1 Plan

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, executed a series of transactions on April 2, 2026.
• These transactions included the exercise of stock options and the subsequent sale of 8,300 shares of common stock at an average price of $146.03 per share.
• Additionally, Mr. Mahon sold a total of 10,178 shares of common stock in multiple tranches at weighted average prices ranging from $559.83 to $571.72 per share.
• These sales were conducted under a Rule 10b5-1(c) trading plan, which was established on August 11, 2025, to satisfy affirmative defense conditions.
• Following these transactions, Mr. Mahon beneficially owns 45,172 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan. While the plan mitigates insider trading concerns, large sales can still signal a lack of immediate upside conviction to the market.

Positives

• The transactions were executed under a Rule 10b5-1(c) plan, indicating adherence to pre-determined trading strategies designed to avoid insider trading concerns.
• The exercise of stock options suggests that the executive is realizing value from equity compensation, potentially indicating a positive view of the company's stock performance at the time of exercise.

Negatives

• A significant number of shares were sold by a key executive, which could be interpreted negatively by the market, despite being executed under a 10b5-1 plan.
• The sale of 10,178 shares at prices significantly higher than the option exercise price ($146.03) represents a substantial divestment of equity.

Risks

• The sale of a large number of shares by a high-ranking executive, even under a 10b5-1 plan, may create negative market sentiment and could be perceived as a lack of confidence in future stock performance.
• The weighted average sale prices indicate that the executive sold shares at prices significantly above the option exercise price, suggesting a realization of substantial gains.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock option exercises and sales are common in the biotechnology and pharmaceutical sectors, where equity-based compensation is prevalent. The use of 10b5-1 plans is a standard practice for executives to manage their stock holdings while adhering to regulatory requirements.

Stakeholder Impact

• Shareholders: May interpret the executive's sale of shares as a negative signal, potentially impacting stock price, although the 10b5-1 plan provides a mitigating factor.
• Employees: May view the executive's realization of gains as a positive indicator of the company's past performance, but could also be concerned about executive confidence.
• Management: The executive is exercising options and selling shares, indicating a personal financial strategy rather than a company-wide directive.

Next Steps

• The reporting person may continue to execute transactions under the existing 10b5-1 plan.
• The company may issue further SEC filings related to executive compensation or stock transactions.

Key Dates

Recommendation

The filing reports routine transactions under a 10b5-1 plan by a key executive. While the sale of a significant number of shares could be a short-term negative signal, the structured nature of the sale under a pre-arranged plan suggests it's not necessarily a reflection of a deteriorating outlook for the company. Therefore, a 'hold' recommendation is appropriate, pending further company-specific news or financial results.

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Insider Trading, Stock Options, 10b5-1 Plan, Beneficial Ownership, Common Stock, Executive Sales